STOCK TITAN

Evogene's nine-month net loss widens to about $10.5M

Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Evogene Ltd. (EVGN) reported nine-month revenue of approximately $0.8 million, compared with $3.2 million in the same period of 2025, and a nine-month net loss of approximately $10.5 million, versus $2.5 million. Third-quarter revenue was approximately $0.1 million, compared with $0.3 million, while the quarter's net loss was approximately $2.9 million versus net income of $5.2 million a year earlier. The company attributed lower nine-month revenue mainly to lower revenue at Casterra; the quarterly comparison reflected the conclusion of its Bayer license and collaboration agreement in May 2026. Prior-year quarterly results included income related to the ICL transaction.

Evogene said its acute graft-versus-host disease drug program generated molecules with biological potency at nanomolar concentrations and preliminary ADME and toxicology profiles; it is optimizing candidates toward IND-enabling studies. Its subsidiary AgPlenus reported compounds active against fungicide-resistant Septoria strains, with selected compounds reducing disease severity by up to 75% in plant-tissue assays versus untreated controls.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • None.

Negative

  • Major pointNine-month net loss widened to approximately $10.5 million from $2.5 million.
  • Moderate pointNine-month revenue fell to approximately $0.8 million from $3.2 million.
  • Minor pointThird-quarter results shifted from $5.2 million net income to a $2.9 million net loss.

Filing Explained

As of September 30, 2026, Evogene reported $9.2 million in cash, cash equivalents and short-term bank deposits, alongside $2.4 million of third-quarter cash use.

Form 6-K is a foreign private issuer’s interim report for material information published in its home market; this filing furnishes Evogene’s third-quarter and nine-month results ended September 30, 2026. Its balance sheet lists 18,052,405 ordinary shares issued and outstanding on September 30, 2026, versus 8,718,193 on December 31, 2025; the higher share count reduces existing holders’ percentage ownership if they did not acquire shares, absent offsetting changes.

For the nine months, the cash-flow statement reports net proceeds of $3,155 thousand from ordinary-share issuance and $3,206 thousand from ordinary shares issued in the warrant-inducement transaction.

The reported $2.4 million of third-quarter cash use included a $0.5 million directors’ and officers’ insurance payment covering 18 months.

Cash, cash equivalents and short-term bank deposits Approximately $9.2 million Consolidated balance as of September 30, 2026
Nine-month revenue Approximately $0.8 million; approximately $3.2 million in 2025 Nine months ended September 30, 2026 and 2025
Nine-month net loss Approximately $10.5 million; approximately $2.5 million in 2025 Nine months ended September 30, 2026 and 2025
Third-quarter revenue Approximately $0.1 million; approximately $0.3 million in 2025 Three months ended September 30, 2026 and 2025
Third-quarter net result Approximately $2.9 million net loss; $5.2 million net income in 2025 Three months ended September 30, 2026 and 2025
Third-quarter research and development expenses Approximately $1.5 million; $1.1 million in 2025 Three months ended September 30, 2026 and 2025
Septoria disease-severity reduction Up to 75% Selected compounds in plant-tissue assays compared with untreated controls
CPV110 IC50 0.4 nM One of the top five molecules in the aGVHD program
aGVHD medical
"acute graft-versus-host disease (aGVHD)"
Acute graft-versus-host disease (aGVHD) is an immune complication that can occur after an allogeneic hematopoietic stem cell or bone marrow transplant, when donor immune cells recognize the recipient’s tissues as foreign and attack them. It typically appears within the first 100 days after transplant and most often affects the skin, gastrointestinal tract (including stomach and intestines), and liver, producing rashes, diarrhea, abdominal pain, nausea, and abnormal liver tests. Severity is classified by clinical grading systems based on the extent and intensity of organ involvement, and management centers on suppressing or modulating the donor immune response. aGVHD is specific to transplants where donor immune cells are present and does not occur with autologous (self) transplants.
ADME medical
"preliminary ADME and toxicology profiles"
ADME stands for Absorption, Distribution, Metabolism and Excretion — the four processes that determine how a drug enters the body, moves to target tissues, is chemically changed, and is removed. For investors, ADME profiles signal whether a drug is likely to be effective, safe and practical to dose; weak ADME can sink a program just like delivery problems can ruin a product launch, while strong ADME improves chances of regulatory approval and commercial success.
IND-enabling studies medical
"advancing the program toward IND-enabling studies"
Ind-enabling studies are early research efforts that test whether a new drug or treatment is safe and effective enough to move forward in development. They are like preliminary tests to ensure a product works as intended before investing more resources into large-scale trials. For investors, these studies are important because successful results can signal potential progress toward bringing a new product to market, impacting its future value.
IC50 medical
"Top 5 molecules IC50 (nM)"
IC50 is the concentration of a drug or compound needed to reduce a specific biological activity by half, commonly used to compare how potent experimental treatments are in laboratory tests. For investors, a lower IC50 often signals a stronger candidate that may require smaller doses, influence development costs, safety margins and competitive positioning, so it offers an early measure of technical promise though it does not guarantee clinical or commercial success.
discontinued operations financial
"Loss from discontinued operations, net"
Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.
mode of action technical
"fungicide discovery programs targeting novel MoA"
The mode of action describes how a medical product produces its effect in the body—what it targets and the steps by which it changes cells, proteins or processes to achieve a therapeutic result. Investors care because this explanation helps regulators, doctors and competitors judge whether the product is likely to work, be safe, or offer advantages over alternatives; think of it like the technical reason a key design opens a particular lock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue did Evogene (EVGN) report for the first nine months of 2026?

Evogene reported approximately $0.8 million in revenue for the first nine months of 2026, versus approximately $3.2 million in the same period of 2025. It attributed the decrease mainly to lower Casterra revenue; the first half of 2025 included approximately $2.0 million in seed sales.

What was Evogene's (EVGN) net loss for the first nine months of 2026?

Evogene's net loss for the first nine months of 2026 was approximately $10.5 million, compared with approximately $2.5 million in 2025. The company attributed the increase primarily to lower revenue, higher financing expenses, and income recognized in connection with the ICL transaction in 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER 

PURSUANT TO RULE 13a-16 OR 15d-16 OF 

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-36187

 

EVOGENE LTD. 

  (Translation of Registrant’s Name into English)

 

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel  

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐ 

 

 

CONTENTS

 

Quarterly Results of Operations

 

On November 19, 2026, Evogene Ltd. (“Evogene”) announced its financial results for the third quarter and nine months ended September 30, 2026. A copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) and is incorporated herein by reference.

 

Evogene is holding a conference call on November 19, 2026 to discuss its quarterly results for the quarter ended September 30, 2026 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference.

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press release dated November 19, 2026, titled “Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026.”
99.2   Slide presentation for the conference call of Evogene held on November 19, 2026, discussing Evogene’s financial results for the third quarter of 2026.

 

Incorporation by Reference

 

The consolidated financial statements tables contained in Exhibit 99.1 to this Form 6-K, which have been prepared in accordance with International Financial Reporting Standards, are incorporated by reference into the registration statements on Form F-3 (SEC File Nos. 333-277565 and 333-294650) and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-259215, 333-286197 and 333-294648) of Evogene, and shall be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 




Date: November 19, 2026
EVOGENE LTD.
(Registrant)

By: /s/ Ofer Haviv
Ofer Haviv
Chief Executive Officer

 

 

 

 

Exhibit 99.1

  

 

 

 

Evogene Reports Financial Results for the Third Quarter and First Nine Months

of 2026, Highlighting Progress in Two Internal Development Programs

 

Company advances its internally developed drug discovery program targeting acute graft-versus-host

disease (aGVHD) and AgPlenus' fungicide discovery programs targeting novel MoA against Septoria

 

Rehovot, Israel – November 19, 2026 - Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN), a computational chemistry company leveraging proprietary AI-driven technologies to design and develop novel small molecules for the pharmaceutical and agricultural industries, today reported its financial results for the third quarter and first nine months of 2026, and provided an update on its business activities.

 

Ofer Haviv, Evogene's President and CEO, stated: "During the third quarter, we continued to advance our strategy of leveraging our proprietary AI-driven discovery platform, ChemPass AI™, to develop innovative small-molecule-based products with significant commercial potential. Alongside our collaborative discovery activities, we are advancing two internal development programs that represent an important component of our strategy to build a pipeline of proprietary assets fully owned and managed by Evogene.

 

The first one is our internal drug discovery program targeting acute graft-versus-host disease (aGVHD), a serious medical condition associated with significant unmet medical need. Within just several months, Using ChemPass AI™, we generated a series of novel, small-molecule candidates, that demonstrated biological potency, at nanomolar concentrations, as well as encouraging preliminary ADME and toxicology profiles. We are now focused on further optimizing these molecules, identifying the most promising candidates, and advancing the program toward IND-enabling studies. (For more information, please see our PR from 28, October 2026)

 

The second program, conducted through our subsidiary AgPlenus, focuses on discovering fungicides with new modes of action targeting Septoria tritici blotch, a major wheat disease for which resistance to existing fungicides is a growing challenge. Using ChemPass AI for Ag™, AgPlenus identified compounds that showed promising activity against fungicide-resistant Septoria strains. Selected compounds also reduced disease severity by up to 75%, compared to untreated controls, in plant tissue assays and demonstrating activity against additional fungal pathogens, indicating broader fungicidal potential. (For more information, please see our PR from 17, November 2026)

 

The progresses achieved across these initiatives demonstrates the ability of ChemPass AI™ and ChemPass AI for Ag™ to translate computational discovery into experimentally validated molecules exhibiting promising biological activity. More importantly, these programs reflect our strategic focus on converting technological capabilities into differentiated, proprietary product candidates offering meaningful commercial potential, ultimately creating long-term value for Evogene and its shareholders. "

 

 

 

Financial Results and Analysis

 

Cash Position

 

As of September 30, 2026, Evogene held consolidated cash, cash equivalents and short-term bank deposits of approximately $9.2 million. Consolidated cash usage during the third quarter of 2026 was approximately $2.4 million, including a Directors' and Officers' insurance payment of approximately $0.5 million, covering an 18-month period.

 

Revenues

 

Revenues for the nine months of 2026 totaled approximately $0.8 million, compared to approximately $3.2 million in the same period of 2025, representing a decrease of approximately $2.4 million. The decrease is mainly attributable to lower revenue recognized by Casterra, which in the first half of 2025 included significant seed sales of approximately $2.0 million. Revenues for the third quarter of 2026 were approximately $0.1 million compared to approximately $0.3 million in the third quarter of 2025, mainly due to the conclusion of the license and collaboration agreement with Bayer in May 2026.

 

Research and Development Expenses

 

Research and development expenses, net of non-refundable grants, for the nine months of 2026 were approximately $4.5 million, compared to approximately $4.6 million in the corresponding period of 2025, representing a decrease of approximately $0.1 million. For the third quarter of 2026, R&D expenses were approximately $1.5 million, an increase from $1.1 million in the same period of 2025. The increase was mainly attributable to the recognition of a non-refundable grant of approximately $0.2 million and an adjustment to liabilities in respect of government grants of approximately $0.1 million, both of which reduced R&D expenses in the third quarter of 2025, as well as the impact of fluctuations in the USD/NIS exchange rate, between the periods.

 

Sales and Marketing Expenses

 

Sales and marketing expenses for the nine months of 2026 were approximately $0.9 million, compared to approximately $1.1 million in the corresponding period of 2025. Sales and marketing expenses for the third quarter of 2026 were approximately $0.2 million, compared to approximately $0.4 million in the third quarter of 2025, primarily due to lower sales and marketing expenses at Casterra and AgPlenus.

 

General and Administrative Expenses

 

General and administrative expenses for the nine months ended September 30, 2026, decreased slightly to approximately $3.1 million, compared to approximately $3.2 million in the corresponding period of 2025. For the third quarter of 2026, general and administrative expenses were approximately $1.1 million, remaining relatively unchanged compared to the same period of 2025. The decrease in general and administrative expenses across Evogene and its subsidiaries was largely offset, mainly by transaction costs associated with the warrant inducement transaction and additional non-recurring legal expenses related to corporate governance and shareholders matters. These costs totaled approximately $0.4 million and $0.3 million during the nine-month and three-month periods ended September 30, 2026, respectively.

 

2 

 

Financing Expenses (Income), Net

 

Financing expenses, net, for the nine months of 2026 were approximately $1.6 million, compared to financing income, net, of approximately $0.9 million in the corresponding period of 2025. This change was primarily related to the accounting treatment and revaluation of warrants, including warrants issued in the August 2024 financing and the February 2026 warrant inducement transaction. As part of the February 2026 warrant inducement transaction, the Company recorded financing expenses of approximately $3.8 million during the first nine months of 2026. In addition, the Company recorded financing income of approximately $2.3 million related to the revaluation of warrants liability as of September 30, 2026. For the third quarter of 2026, financing income, net, was approximately $176 thousand, compared to approximately $79 thousand in the corresponding period of 2025, with no material change between the periods.

 

Loss from Discontinued Operations

 

Loss from discontinued operations, net, for the nine months of 2026 was approximately $0.5 million, compared to an income from discontinued operations, net, of approximately $4.0 million in the corresponding period of 2025. For the third quarter of 2026, the loss from discontinued operations was approximately $0.06 million, compared to income of approximately $7.6 million in the third quarter of the previous year. These amounts primarily reflect the financial results of Lavie Bio's and Biomica's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single-line item in the consolidated statements of profit and loss. Following the sale of the majority of Lavie Bio's assets, as well as Evogene's MicroBoost AI for Ag, to ICL in July 2025 and the licensing agreement with Lishan in February 2026, Lavie Bio's and Biomica's operating expense levels have decreased significantly. Biomica's operations were classified as discontinued operations beginning in the second quarter of 2026, and accordingly, the 2025 comparative figures have been reclassified to conform to the current period presentation. Lavie Bio's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, had already been classified as discontinued operations in 2025.

 

Net Loss

 

Net loss for the nine months ended September 30, 2026, was approximately $10.5 million, compared to approximately $2.5 million in the corresponding period of 2025. The $8.0 million increase in net loss was primarily attributable to lower revenues, higher financing expenses, and income recognized in connection with the ICL transaction during the corresponding period of 2025. For the third quarter of 2026, net loss was approximately $2.9 million, compared to net income of approximately $5.2 million in the same period of 2025. The change was primarily attributable to income recognized in connection with the ICL transaction during the third quarter of 2025, as discussed above.

 

About Evogene Ltd.

 

Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AITM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

 

For more information, please visit www.evogene.com.

 

3 

 

About AgPlenus Ltd. 

 

AgPlenus, a subsidiary of Evogene Ltd., is an AI-driven crop protection discovery company focused on developing effective and sustainable solutions to address the growing challenge of pesticide resistance. The company leverages ChemPass AI for Ag™, a technology platform licensed from Evogene, integrating predictive biology, artificial intelligence, and computational chemistry to discover novel crop-protection molecules. Through its target-based discovery approach, AgPlenus aims to improve discovery efficiency, reduce development risks, and advance differentiated crop-protection solutions with the potential to address unmet agricultural needs. 

 

For more information, please visit www.agplenus.com

 

Forward-Looking Statements

 

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as “may,” “could,” “expects,” “hopes,” “intends,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates,” “demonstrates” or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses, among other things: its advancing its existing pharmaceutical and agricultural division programs toward subsequent stages of development; its potential, future revenue generation as its pharmaceutical programs progress through development and toward commercialization; its potential establishment of additional collaborations with leading biotechnology and pharmaceutical companies; its advancement of its internal high-value programs, including its internal drug discovery program under which proprietary molecules have the potential to serve as candidates for future preclinical development; its discovery program for new fungicides via AgPlenus; pursuit of strategic partnerships in agriculture; its continuing to strengthen its computational platform; and its ability to execute its strategy and create long-term shareholder value.

 

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including: the aftermath of the recent wars between Israel and the United States, on the one hand, and Iran and its proxy terrorist groups, Hamas, Hezbollah, and, intermittently, the Houthis in Yemen, on the other hand, (and any destabilizations in Israel, neighboring territories or the Middle East region resulting from those wars; Evogene’s and its subsidiaries’ reliance on third parties to conduct certain activities, such as field-trials and pre-clinical studies, which could cause significant delays in the conduct of those activities; the potential impact of a change of control of Evogene’s board of directors due to the actions of dissident shareholders; as well as those additional risk factors identified in Evogene’s reports filed with the applicable securities authority. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Evogene’s actual results to differ from those reflected in its forward-looking statements, please see “Item 3.D. Risk Factors” in Evogene’s Annual Report on Form 20-F for the year ended December 31, 2025, and its subsequent reports filed with or furnished to the U.S. Securities and Exchange Commission and Israeli Securities Authority. You should not place undue reliance on any forward-looking statements included in this press release. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions, except to the extent required by applicable law.

 

Investor Relations Contact:

 

ir@evogene.com
Tel: +972-8-9311901

 

4 

 

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION 

U.S. dollars in thousands

 

   September 30,   December 31, 
   2026   2025 
   Unaudited     
ASSETS          
CURRENT ASSETS:          
Cash and cash equivalents  $8,571   $12,956 
Restricted cash   33    32 
Short-term bank deposits   655    - 
Trade receivables   232    317 
Other receivables and prepaid expenses   1,181    1,565 
Deferred expenses related to issuance of warrants   -    551 
Inventories   65    210 
           
    10,737    15,631 
LONG-TERM ASSETS:          
Long-term deposits and other receivables   5    571 
Investment accounted for using the equity method   -    43 
Deferred expenses related to issuance of warrants   -    1,165 
Right-of-use-assets   1,446    1,824 
Property, plant and equipment, net   446    812 
           
    1,897    4,415 
           
TOTAL ASSETS  $12,634   $20,046 
           
LIABILITIES AND EQUITY          
           
CURRENT LIABILITIES:          
Trade payables  $593   $639 
Employees and payroll accruals   703    861 
Lease liabilities   618    716 
Liabilities in respect of government grants   142    56 
Deferred revenues and other advances   21    17 
Warrants and pre-funded warrants liability   496    706 
Other payables   389    449 
           
    2,962    3,444 
LONG-TERM LIABILITIES:          
Lease liabilities   1,287    1,482 
Liabilities in respect of government grants   3,082    3,073 
Deferred revenues and other advances   60    72 
           
    4,429    4,627 
           
TOTAL LIABILITIES  $7,391   $8,071 

 

5 

 

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands

 

SHAREHOLDERS' EQUITY:        

Ordinary shares of NIS 0.2 par value:
Authorized - 30,000,000 ordinary shares; Issued and

outstanding – 18,052,405 ordinary shares on September

30, 2026 and 8,718,193 ordinary shares on December

31, 2025

   1,103    488 
Share premium and other capital reserves   288,212    281,986 
Accumulated deficit   (293,043)   (282,556)
           
Equity attributable to equity holders of the Company   (3,728)   (82)
           
Non-controlling interests   8,971    12,057 
           
TOTAL EQUITY   5,243    11,975 
           
TOTAL LIABILITIES AND EQUITY  $12,634   $20,046 

 

6 

 

CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS

U.S. dollars in thousands (except share and per share amounts)

 

  

Nine months ended 

September 30,

  

Three months ended 

September 30, 

   Year ended December 31, 
   2026   2025(*)   2026   2025(*)   2025(*) 
   Unaudited   Audited 
                     
Revenues  $822   $3,189   $141   $312   $3,503 
                          
Cost of revenues:                         
   Inventory impairment   -    -    -    -    2,180 
   Other cost of revenues   428    1,810    92    157    1,914 
Total Cost of Revenues   428    1,810    92    157    4,094 
                          
Gross profit   394    1,379    49    155    (591)
Operating expenses:                         
                          
Research and development, net   4,466    4,635    1,528    1,133    6,262 
Sales and marketing   908    1,061    200    358    1,359 
General and administrative   3,096    3,154    1,112    1,091    4,021 
Other expenses (income)   293    (191)   191    -    (205)
                          
Total operating expenses, net   8,763    8,659    3,031    2,582    11,437 
                          
Operating loss   (8,369)   (7,280)   (2,982)   (2,427)   (12,028)
                          
Financing income   2,559    2,352    255    513    2,618 
Financing expenses   (4,124)   (1,445)   (79)   (434)   (1,841)
                          
Financing income (expenses), net   (1,565)   907    176    79    777 
                          
Share of loss from equity accounted investment   (43)   (82)   -    (16)   (39)
                          
Loss before taxes on income   (9,977)   (6,455)   (2,806)   (2,364)   (11,290)
Taxes on income (tax benefit)   -    1    -    -    1 
Loss from continuing operations   (9,977)   (6,456)   (2,806)   (2,364)   (11,291)
Income (loss) from discontinued operations, net   (548)   3,983    (56)   7,561    3,464 
                          
Net income (loss)  $(10,525)  $(2,473)  $(2,862)  $5,197   $(7,827)
                          
Attributable to:                         
Equity holders of the Company  $(10,487)  $(3,176)  $(2,849)  $3,874    (8,485)
Non-controlling interests   (38)   703    (13)   1,323    658 
                          
   $(10,525)  $(2,473)  $(2,862)  $5,197   $(7,827)
Basic and diluted loss per share from continuing operations, attributable to equity holders of the Company  $(0.75)  $(0.84)  $(0.17)  $(0.27)  $(1.41)
Basic and diluted loss per share from discontinued operations, attributable to equity holders of the Company  $(0.04)  $0.42   $(0.00)  $0.71   $0.33 
                          
Weighted average number of shares used in computing basic and diluted loss per share   13,245,869    7,588,486    16,894,446    8,716,424    7,874,039 

 

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

 

7 

 

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

 

  

Nine months ended 

September 30, 

  

Three months ended 

September 30, 

   Year ended December 31, 
   2026   2025(*)   2026   2025(*)   2025(*) 
   Unaudited   Audited 
Cash flows from operating activities                         
                          
Loss from continuing operations  $(9,977)  $(6,456)  $(2,806)  $(2,364)  $(11,291)
                          
Adjustments to reconcile loss to net cash used in operating activities:                         
                          
Adjustments to the profit or loss items:                         
                          
Depreciation of property, plant and equipment and right-of-use-assets   501    748    167    241    971 
Impairment of Property, Plant and Equipment   116    -    -    -    - 
Inventory impairment   -    -    -    -    2,180 
Share-based compensation   80    570    (13)   125    728 
Remeasurement of Convertible SAFE   -    (371)   -    (26)   (371)
Net financing expenses (income)   (73)   21    (81)   (135)   (28)
Loss (gain) from sale of property, plant and equipment   (17)   (192)   (3)   2    (205)
Revaluation of government grants   27    24    18    24    40 
Amortization of deferred expenses related to issuance of warrants   1,716    989    -    333    1,323 
Remeasurement of pre-funded warrants and warrants   (2,271)   (1,664)   (163)   (346)   (1,781)
Expenses related to warrants inducement transaction   2,095    -    -    -    - 
Share of loss of an associate   43    82    -    15    39 
Allowance for doubtful accounts   78    -    78    -    - 
Investment in sub-lease   194    -    194    -    - 
Taxes on income (tax benefit)   -    1    -    -    (6)
                          
    2,489    208    197    233    2,890 
Changes in asset and liability items:
                         
Decrease in trade receivables   7    667    74    730    665 
Decrease (increase) in other receivables and prepaid expenses   (114)   870    (388)   (417)   958 
Decrease (increase) in inventories   145    (740)   28    (139)   (1,019)
Increase (decrease) in trade payables   62    (195)   187    (31)   (40)
Decrease in employees and payroll accruals   (143)   (335)   (204)   (226)   (494)
Increase (decrease) in other payables   16    (343)   117    (45)   (344)
Decrease in deferred revenues and other advances   (8)   (356)   (5)   (5)   (361)
                          
    (35)   (432)   (191)   (133)   (635)

 

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

 

8 

 

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

 

  

Nine months ended 

September 30,

  

Three months ended 

September 30, 

   Year ended December 31, 
   2026   2025(*)   2026   2025(*)   2025(*) 
   Unaudited   Audited 
Cash received (paid) during the period for:                    
                     
Interest received   246    221    46    45    338 
Interest paid   (104)   (221)   (20)   (70)   (256)
Taxes paid   (5)   (11)   -    -    (11)
                          
Net cash used in continuing operating activities   (7,386)   (6,691)   (2,774)   (2,289)   (8,965)
                          
Net cash provided by (used in) discontinued operations activities   (287)   (4,125)   13    (1,044)   (4,537)
                          
Net cash used in operating activities  $(7,673)  $(10,816)  $(2,761)  $(3,333)  $(13,502)
                          
Cash flows from investing activities:                         
                          
Purchase of property, plant and equipment  $(13)   (129)   (2)   (7)  $(199)
Proceeds from sale of property, plant and equipment   115    10    3    10    78 
Proceeds from finance sub-lease asset   17    29    -    12    52 
Investment in bank deposits, net   (655)   (3,700)   (655)   (2,699)   (1)
                          
Net cash provided by (used in) continuing investing activities   (536)   (3,790)   (654)   (2,684)   (70)
                          
Net cash provided by (used in) discontinued investing activities   483    11,265    483    13,593    17,808 
                          
Net cash provided by (used in) investing activities  $(53)  $7,475   $(171)  $10,909   $17,738 

 

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

 

9 

 

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

 

  

Nine months ended

September 30,

  

Three months ended 

September 30, 

   Year ended December 31, 
   2026   2025(*)   2026   2025(*)   2025(*) 
   Unaudited   Audited 
Cash flows from financing activities:                         
                          
Proceeds from issuance of ordinary shares, net of issuance expenses   3,155    4,283    2,350    -    4,283 
Proceeds from issuance of ordinary shares in warrant inducement transaction, net of issuance expenses   3,206    -    -    -    - 
Repayment of lease liability   (334)   (315)   (121)   (87)   (423)
Dividend paid by subsidiary   (2,672)   -    -    -    - 
Repayment of convertible SAFE   -    (10,000)   -    (10,000)   (10,000)
Proceeds from government grants   101    -    -    -    - 
Repayment of government grants   (34)   (122)   (14)   -    (244)
                          
Net cash provided by (used in) continuing financing activities   3,422    (6,154)   2,215    (10,087)   (6,384)
                          
Net cash used in discontinued financing activities   (80)   (192)   (30)   (249)   (218)
                          
Net cash provided by (used in) financing activities  $3,342   $(6,346)  $2,185   $(10,336)  $(6,602)
                          
Exchange rate differences - cash and cash equivalent balances   (1)   12    2    (13)   21 
                          
Decrease in cash and cash equivalents   (4,385)   (9,675)   (745)   (2,773)   (2,345)
                          
Cash and cash equivalents, beginning of the period   12,956    15,301    9,316    8,329    15,301 
Cash and cash equivalents presented in assets held for sale   -    -    -    70    - 
                          
Cash and cash equivalents, end of the period  $8,571   $5,626   $8,571   $5,626   $12,956 
                          
Significant non-cash activities                         
Acquisition of property, plant and equipment  $-   $2   $-   $-   $2 
Right-of-use asset recognized with corresponding lease liability  $33   $207   $-   $-   $207 
Exercise of pre-funded warrants  $-   $389   $-   $-   $389 
Derecognition of property, plant and equipment under a finance lease  $-   $13   $-   $-   $13

 

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

 

10

 

 

 

Exhibit 99.2

 

˥ November 19, 2026 EARNINGS CALL Q 3 2026

 

 

FORWARD LOOKING STATEMENT This presentation contains "forward - looking statements" relating to future events, and Evogene Ltd. ( the “ Company ”) , may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward - looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws , as amended. Statements that are not statements of historical fact may be deemed to be forward - looking statements . Such forward - looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward - looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing , product development and launches, estimated market size s and milestones , pipeline, as well as our capabilities and technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward - looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward - looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of ( i ) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any destabilizations in Israel, neighboring territories or the Middle East region, and those described in greater detail in Evogene's Annual Report on Form 20 - F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors” . Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company , nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company . The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services . 2

 

 

˧ EARNINGS CALL Q3 2026 AGENDA • CEO Update – By Ofer Haviv • VP Finance Update – By Polina Ravzin • Q&A

 

 

4 PHARMA DIVISION • aGVHD is a life - threatening complication of hematopoietic stem cell transplantation, affecting approximately 30 % – 40 % of transplant recipients • Global GVHD treatment market is estimated at $ 2 B annually, with steroid - refractory aGVHD form estimated market of $ 0 . 5 B with a strong clinical unmet need • Target : key cellular protein expressed in a wide range of cell types involved in cell motility, structure and immune regulation • Combines ChemPass AI TM novel molecule generation capabilities with program guidance of world - renowned experts in the field INTERNALLY DEVELOPED DRUG DISCOVERY PROGRAM NOVEL SMALL - MOLECULE THERAPIES FOR STEROID - REFRACTORY ACUTE GRAF T - VERSUS - HOST DISEASE ( a GVHD ) STRUCTURE OF BINDING SITE AND PUTATIVE LIGAND

 

 

5 PHARMA DIVISION INTERNALLY DEVELOPED DRUG DISCOVERY PROGRAM FOR AGVHD EXPERIMENTAL RESULTS HIT ID - CHEMICAL SPACE DIFFERENTIATION WITH POINTHIT TM (STEP 1 )  Identified active candidates represent different chemical space from the known inhibitors EFFICIENT HIT EXPANSION THROUGH ACTIVESEARCH TM (STEP 2 ) Lead candidates show better - than - expected efficiency NOVEL MOLECULE GENERATION USING LEADOPGPTTM (STEP 3 ) first batch ordered and awaits experimental validation HIT ID 22 (23%) Enzymatic Activity 95 Ordered Compounds 10 µM HIT TO LEAD 116 63 (53%) Ordered Compounds Enzymatic Activity 1 µM Dr. Corey Cutler Dana - Farber Cancer Institute and HMS Prof. Dr. Robert Zeiser University of Freiburg Top 5 molecules IC50( nM ) Compound 0.4 CPV110 2.7 CPV128 4.1 CPV161 4.9 CPV138 7.4 CPV205

 

 

AGPLENUS SEPTORIA INTERNAL PROGRAM 6 EVOGENE'S SUBSIDIARY [1] Hehir et al. (2018). Plant Pathology, 67, 573 – 583. DOI [2] Andresen et al. (2026). European Journal of Plant Pathology. DOI ௗ ௗ MAJOR WHEAT DISEASE Leads to major wheat yield losses, ranking 1 st in Europe, and 2 nd in the US THE CHALLENGE & NEED MARKET OPPORTUNITY > 70 % of fungicide use in Europe. Estimated opportunity: ~€ 1.2 billion 1 . RISING RESISTANCE Reduced sensitivity to azoles and SDHIs calls for new modes of action 2 AGPLENUS STRATEGY New fungicide modes of action ChemPass AI + experimental discovery Optimize potency and plant - tissue efficacy Target resistant strains and other pathogens

 

 

AGPLENUS SEPTORIA – REPRESENTATIVE RESULTS AG20133 - COMPOUND PERFORMANCE 7 EVOGENE'S SUBSIDIARY 0.01 0.1 1 10 100 1000 0 25 50 75 100 Inhibitor concentration (μM) A c t i v i t y ( % ) TARGET I NHIBITION ( ENZYME IC ₅₀ 3 ΜM Ͻ ) ANTIFUNGAL A CTIVITY (INCLUDING RESISTANT STRAINS) DISEASE R EDUCTION IC₅₀ (µM) Pathogen / strain 34 Septoria wild type 33 Septoria DMI resistan t 26 Septoria SDHI resistant 33 Septoria Qol resistant 35 Other fungal pathogen High protein binding & inhibition Results verified by a n external research organization 75% Disease inhibition

 

 

8 PHARMA DIVISION – Drugs Demyelination Disorders Neutrophil - Derived Inflammatory Diseases Metabolic Disease Therapy Resistant Lung  Cancer​ Herbicides INTERNAL PIPELINE Wheat leaf Blotch (Two targets) AG DIVISION* – Ag - Chemicals AG DIVISION ͐ – Operations in this field are conducted through our subsidiary, AgPlenus . Cardiovascular Diseases HARNESSING THE POWER OF CHEMPASS AI FOR REAL - WORLD INNOVATION On cology Disease UNDISCLOSED INTERNAL PIPELINE Undisclosed INTERNAL PIPELINE Acute GVHD

 

 

˭ EARNINGS CALL Q3 2026 AGENDA • CEO Update – By Ofer Haviv • VP Finance Update – By Polina Ravzin • Q&A

 

 

˥ˤ VP FINANCE UPDATE FINANCIAL HIGHLIGHTS

 

 

˥˥ VP FINANCE UPDATE FINANCIAL HIGHLIGHTS (*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

 

 

˥˦ EARNINGS CALL Q 3 2026 AGENDA • CEO Update – By Ofer Haviv • VP Finance Update – By Polina Ravzin • Q&A

 

 

THANK YOU

 

Filing Exhibits & Attachments

2 documents

Keep reading